Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering
April 06 2021 - 4:01PM
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage
biopharmaceutical company developing precision T cell therapies to
treat solid tumors, today announced the closing of its previously
announced initial public offering in the United States of 9,750,000
American Depositary Shares (“ADSs”) representing
9,750,000 ordinary shares, at an initial public offering price
of $18.00 per ADS. The gross proceeds to Achilles from the
offering were approximately $175.5 million. All ADSs sold in the
offering were offered by Achilles.
J.P. Morgan, BofA Securities and Piper Sandler
acted as joint book-running managers for the offering. Chardan,
Oppenheimer & Co, and Kempen & Co acted as co-managers.
A registration statement relating to these
securities became effective on March 30, 2021. The securities
referred to in this announcement were offered only by means of a
prospectus. Copies of the preliminary prospectus relating to and
describing the terms of the proposed IPO can be obtained from the
following sources:
- J.P. Morgan Securities LLC, Attention Equity Syndicate Desk,
383 Madison Avenue, New York, New York 10179, or via email:
prospectuseq_fi@jpmchase.com;
- BofA Securities, Attention: Prospectus Department,
NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC
28255-0001, or via email: dg.prospectus_requests@bofa.com; or
- Piper Sandler & Co., Attention:
Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN
55402, by telephone: (800) 747-3924, or via email:
prospectus@psc.com.
About Achilles
TherapeuticsAchilles is a clinical-stage,
biopharmaceutical company developing precision T cell therapies
targeting clonal neoantigens: protein markers unique to the
individual that are expressed on the surface of every cancer cell.
The Company has two ongoing Phase I/IIa trials, the CHIRON trial in
patients with advanced non-small cell lung cancer (NSCLC) and the
THETIS trial in patients with recurrent or metastatic melanoma.
Achilles uses DNA sequencing data from each patient, together with
its proprietary PELEUS™ bioinformatics platform, to identify clonal
neoantigens specific to that patient, and then develop precision T
cell-based product candidates specifically targeting those clonal
neoantigens.
Lee M. Stern – VP, IR & External
Communications+1 (332) 373-2634l.stern@achillestx.com
Consilium Strategic CommunicationsMary-Jane
Elliott, Sukaina Virji, Melissa Gardiner+44 (0) 203 709
5000achillestx@consilium-comms.com
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Jul 2023 to Jul 2024